EDAP TMS SA quarterly report, Q3 FY2026

EDAP TMS S.A. — Form 10-Q Summary

Reporting period: Quarter and nine months ended September 30, 2026. Unaudited U.S. GAAP financial statements; amounts below are U.S. dollars unless stated otherwise. Effective January 1, 2026, EDAP became a U.S. domestic issuer. The continuing business is HIFU, centered on the Focal One robotic focal-therapy platform.

Key financial results

MetricQ3 2026Q3 20259M 20269M 2025
Revenue$9.8m$7.8m$34.6m$23.8m
Gross profit / margin$5.1m / 51.4%$3.6m / 46.6%$18.4m / 53.0%$11.7m / 48.9%
Operating loss$7.8m$6.7m$23.8m$20.0m
Net loss, including discontinued operations$4.5m$5.9m$28.0m$19.8m
Basic and diluted loss per share$0.10$0.16$0.71$0.53
  • Revenue growth reflected higher equipment and treatment-driven sales. EDAP sold 7 Focal One units in Q3 (2 in the U.S.), versus 6 (3 in the U.S.) a year earlier; nine-month sales were 31 units (15 in the U.S.), versus 21 (10 in the U.S.).
  • Q3 treatment-driven revenue rose 24.3% to $4.8m; nine-month treatment-driven revenue increased 30.7% to $14.3m. Management attributed improved gross margins primarily to lower Focal One standard costs and better fixed-cost absorption at higher production volumes.
  • Operating expenses rose 24.4% in Q3 and 33.0% for nine months, led by selling and marketing costs. General and administrative expense also increased, partly due to the transition to domestic filer status.
  • Q3 net loss narrowed year over year, partly reflecting $2.0m of net financial income, including a warrant fair-value gain. Nine-month net loss widened, with $6.0m of net financial expense, primarily related to EIB warrant fair-value changes and loan interest.

Cash, debt and liquidity

  • Cash and cash equivalents were $56.3m at September 30, 2026, up from $20.5m at year-end 2025. Current assets were $94.8m and current liabilities $36.1m; these totals include assets and liabilities classified as discontinued operations.
  • For nine months, operating cash use was $10.7m (versus $14.0m in 2025), investing cash use was $3.4m, and financing provided $50.7m. Cash flow statements do not separately present discontinued-operation cash flows.
  • Financing included approximately $42.4m net proceeds from an August ADS offering and $14.0m net proceeds from EIB borrowings, partly offset by debt and lease repayments and lower short-term borrowings.
  • Reported long-term debt was $35.6m, including current and non-current portions; the debt note includes EIB warrant liabilities in its debt-facility presentation. Short-term borrowings were $0.4m in continuing operations and $1.1m in discontinued operations.
  • Management believes available funds are sufficient for at least 12 months from issuance of the interim statements, while expecting operating losses to continue. The EIB facility provides for up to €36m in tranches, subject to conditions; Tranches A and B had been drawn by period-end.

Material changes, outlook and risks

  • In May 2026, the board approved plans to exit the ESWL and Distribution segments and focus on HIFU. Those businesses, which represented approximately 47% of consolidated 2025 revenue, are presented as discontinued operations for all periods. Their combined Q3 2026 revenue was $7.2m and nine-month revenue was $19.0m.
  • EDAP expects sales, transfers, or orderly wind-downs of the discontinued businesses within one year of held-for-sale classification. It had no definitive sale agreement as of the report date. No impairment was recorded on classification. Certain transition support and continuing ESWL spare-parts obligations may remain; EIB facility terms may require some disposal proceeds to repay borrowings.
  • No specific earnings or revenue guidance is provided. Management cites continued HIFU commercialization, product adoption, expense management, and financing needs as important to achieving profitability and positive operating cash flow. Additional financing may be needed if liquidity or capital requirements differ from expectations.
  • Key risks include execution delays or costs in the planned exits, near-term revenue disruption, HIFU market acceptance and regulatory or reimbursement uncertainty, ongoing losses and financing requirements, EIB warrant valuation volatility, currency fluctuations, competition, and reliance on suppliers and distribution partners. The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material changes to previously disclosed risk factors other than the discontinuation risk.
  • Management concluded disclosure controls were effective as of September 30, 2026; no materially affecting change in internal control over financial reporting was reported.

Important facts for investors to verify

  • Progress, expected timing, transaction terms, and possible continuing obligations for the ESWL and Distribution exits; confirm whether EIB repayment provisions affect proceeds or debt classification.
  • Whether HIFU revenue growth and improving gross margin can offset higher selling, marketing, and administrative costs and continuing operating losses.
  • Cash runway and future financing needs, including EIB facility conditions, interest costs, and the potential effects of warrant remeasurement.
  • Offering-related dilution: 9,688,750 ADSs were issued in August; outstanding ordinary shares were 47,220,589 as of November 5, 2026.
  • Confirm the company’s current trading symbol and corporate identity: the filing cover lists “FOCL,” while the registrant is EDAP TMS S.A. and the filing describes a FocalTherics rebrand.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.